- Home
- CHRD vs IBRX Comparison
CHRD vs IBRX Comparison
Compare CHRD & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHRD | IBRX |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 7.5B |
| IPO Year | 2010 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CHRD | IBRX |
|---|---|---|
| Price | $134.46 | $7.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $149.17 | $12.57 |
| AVG Volume (30 Days) | 770.4K | ★ 8.7M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ 11.14 | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $12.56 | $88.59 |
| Revenue Next Year | N/A | $131.15 |
| P/E Ratio | $12.39 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $84.25 | $1.95 |
| 52 Week High | $151.95 | $12.43 |
Technical Indicators
Market Signals| Indicator | CHRD | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.71 | 52.38 |
| Support Level | $129.88 | $6.68 |
| Resistance Level | $141.76 | $8.46 |
| Average True Range (ATR) | 4.66 | 0.38 |
| MACD | -0.12 | 0.08 |
| Stochastic Oscillator | 46.30 | 77.78 |
Price Performance
Historical ComparisonAbout CHRD Chord Energy Corporation
Chord Energy Corp is an independent exploration and production (E&P) company engaged in the acquisition, exploration, development and production of crude oil, NGL and natural gas prominently in the Williston Basin, with limited non-operated interests in the Marcellus Shale. It operates in one reportable business segment, which is the E&P of crude oil, NGL and natural gas. The company derives revenue from the sale of crude oil, NGL and natural gas production.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.